eXmoor and Virica receive funding to improve AAV gene therapy manufacturing

Virica Biotech and eXmoor Pharma have announce a new collaboration project funded by a joint UK-Canada government initiative.  This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies.  The collaborative project will utilize Virica’s VSEs™, small molecules that have been shown to increase productivity of AAVs, leveraging eXmoor’s scale-up process development expertise to identify top candidates and deploy them at commercial scale upon completion of the project next year.

Press Release: https://www.businesswire.com/news/home/20241017137541/en/eXmoor-and-Virica-receive-funding-to-improve-AAV-gene-therapy-manufacturing

Learn more about eXmoor Pharma’s CDMO services for Cell and Gene Therapies Here